Methods of making and using universal centralized influenza vaccine genes

A vaccine and vaccination technology, applied in the field of vaccines, can solve serious pneumonia, death and other problems

Pending Publication Date: 2021-09-21
BOARD OF RGT UNIV OF NEBRASKA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when associated with other pathogens of porcine respiratory disease sy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of making and using universal centralized influenza vaccine genes
  • Methods of making and using universal centralized influenza vaccine genes
  • Methods of making and using universal centralized influenza vaccine genes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0228] Example 1 - Viral gene and generated vaccine sequence

[0229] The genetic relationship between the vaccine gene and the wild-type circulating gene described herein is shown in Figures 9- 23. Since the vaccine genes described herein are prepared using all unique HA sequences, they are unlike any genes prepared using other strategies such as common sequence, Cobra, Mosaics, and COT.

[0230] The unique universal vaccine gene described herein is used to resist human A influenza viruses (H1, H2, H3, H5, N1 and N2 (SEQ ID NO: 1-43)), human fluorinated virus (HA mountain shape, HA Victoria, Na Mountain Class, NA Victoria (SEQ ID NO: 44-74)) and pig Aflu virus (H1, H3, N1 and N2 (SEQ ID NO: 75-102)), and can be applied to A general influenza vaccine is produced for all known influenza strains. Nucleic acid sequences encoding representative flu vaccines are shown in SEQ ID NO: 103-122.

Embodiment 2

[0231] Example 2 - Preliminary results

[0232] The Animal Use protocol approved by the Association for Assessment Acreditation of Laboratory Animal Care (Aalac) is used according to the Laborative Animal Care, Aalac. The ASSOCIMAL CARE, AALAC is used to place all animals in UNL Life Sciences Annex. All animal experiments are in accordance with the provisions of Animal Welfare Act, PHS Animal WelfarePolicy, NiH Guide for the Care and Use Oflaborative Animals, and UNL Policy Cuts with procedures.

[0233] Gender as a biological variable. Only female mice were used in vivo studies. However, all successful vaccine candidates were confirmed in the study of male mice.

[0234] Biological hazard. All biohazard materials have been approved by the UNL mechanism Biosafety Committee (IBC). UNL IBC is responsible for the safe use of the infection and recombinant DNA in the UNL laboratory. This study did not use any reagents that rating higher than BSL2.

[0235] Strictness and transparency....

Embodiment 3

[0269] Example 3 - Representative sequence comparison

[0270] As shown in Table 1, sequences of the selected vaccine polypeptides described herein are compared to each other.

[0271] Table 1. Comparison of the sequence of influenza H1 HA protein sequence

[0272]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This disclosure describes a number of different polypeptide sequences, and the nucleic acid sequences encoding such polypeptide sequences, that can be used alone or in combination as universal vaccines (e.g., against influenza A or influenza B in humans or influenza in swine).

Description

Technical field [0001] The present disclosure generally relates to vaccines and specifically involves influenza vaccines. Background technique [0002] In 1931, the influenza virus was identified as a pathogen of the pig. Two years later, in 1933, the flu virus was found in humans. [0003] Every year, 5% -15% of the world's population are affected by epidemics and have upper respiratory tract infections, and 3 million to 5 million have severe diseases, and 250,000 to 500,000 cases lead to death (WHO 2009). In the United States, the annual seasonal influenza has a population of 20%, leading to 200,000 hospitalization and approximately 37,000 deaths. The World Health Organization (WHO) pointed out that "the flu is quickly spread to the world with seasonal epidemics, and has caused considerable economic burden in the form of hospitals and other health care costs and productivity. In the United States of America, it is estimated that every year The popular cost is as high as 167 bil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/145A61P31/16C07K14/11C12N15/44
CPCA61K39/12C12N2760/16134A61K2039/55555A61K39/145C12N7/00C12N2710/10034C12N2740/10034C12N2750/14134C12N2760/18034C12N2760/20034C12N2770/36134
Inventor E·A·韦弗
Owner BOARD OF RGT UNIV OF NEBRASKA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap